Antares Pharma Competitors and Similar CompaniesClear all

Antares Pharma's competitors and similar companies include Avedro, Duchesnay, Medexus Pharma and Dong-A ST.

	Antares Pharma Antares Pharma is a specialty pharmaceutical company which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.	Avedro Avedro is a medical device and pharmaceutical company that produces and delivers drugs and devices for corneal remodeling to eye care professionals.	Duchesnay Duchesnay is a research-based pharmaceutical company.	Medexus Pharma Medexus Pharma is a pharmaceutical company developing therapies for autoimmune diseases and cancer.	Dong-A ST Dong-A ST is a healthcare company that specializes in the development of ethical drugs and medical devices.
Founding Date	Founding Date 1979	Founding Date 2002	Founding Date 1970	Founding Date 2012	Founding Date 1932
Type	Type Public	Type Subsidiary	Type Private	Type Subsidiary	Type Public
Tags	Tags Healthcare diabetes drug development healthtech medical devices medtech pharma	Tags Healthcare drug development medical devices pharma	Tags Healthcare drug development medical devices medtech pharma women's health	Tags Healthcare drug development medical devices medtech oncology pharma	Tags Healthcare biotech drug development medical devices medtech pharma
Locations	Locations Ewing, US HQ Hopkins, US Plymouth, US	Locations Waltham, US HQ	Locations Blainville, CA HQ Bryn Mawr, US	Locations Chicago, US HQ	Locations HQ
Employees	Employees 1788% increase	Employees 122	Employees 911% increase	Employees 106	Employees 1,533
Financial
Revenue (est.)	Revenue (est.) $184m (FY, 2021)	Revenue (est.) $27.7m (FY, 2018)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₩808.8b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $10.9m (FY, 2018)	Cost of goods N/A	Cost of goods N/A	Cost of goods ₩456.1b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $16.8m (FY, 2018)	Gross profit N/A	Gross profit N/A	Gross profit ₩356.5b (FY, 2025)
Net income	Net income $46.3m (FY, 2021)	Net income ($25.1m) (FY, 2018)	Net income N/A	Net income N/A	Net income (₩37.6b) (FY, 2025)